文献速递慢性肾脏病血液净化与透析肾移植

如何在肥胖合并慢性肾脏病患者中个体化肾脏保护治疗:ERA糖尿病肥胖工作组的评论

How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

本文由ERA糖尿病肥胖工作组撰写,聚焦胰高血糖素样肽-1受体激动剂(GLP-1RA)在超重/肥胖合并2型糖尿病的慢性肾脏病(CKD)患者中的作用,总结改善全球肾脏病预后组织(KDIGO)CKD指南推荐并强调新证据,探讨其他肠激素疗法及非甾体盐皮质激素受体拮抗剂(nsMRA)等多靶点治疗,并指出多靶点治疗时机与顺序的未知点及未来优先研究问题。

要点

  • GLP-1RA在糖尿病肥胖合并CKD患者中具有肾脏保护作用,FLOW试验提供支持证据。
  • KDIGO CKD指南推荐已总结,指南发布后的新证据被重点强调。
  • 多靶点治疗(RAS抑制剂、SGLT2抑制剂、肠促胰素治疗、nsMRA)可能改善心肾结局,但时机与顺序未知。

核心结论

  • GLP-1RA在超重/肥胖合并2型糖尿病的CKD患者中具有肾脏保护作用,FLOW试验等临床研究支持其应用。
  • 其他肠激素疗法(替西帕肽、三重激动剂、胰淀素类似物)及nsMRA等新型疗法可能改善心血管和肾脏结局。
  • 包含RAS抑制剂、SGLT2抑制剂、肠促胰素治疗和nsMRA的多靶点治疗可能改善超重/肥胖合并2型糖尿病CKD患者的心肾结局,但治疗时机与顺序尚不明确。

研究设计与样本

  • 本文为ERA糖尿病肥胖工作组的评论,总结KDIGO CKD指南推荐并回顾支持GLP-1RA作用的临床研究(包括FLOW试验),探讨其肾脏保护潜在机制及其他肠激素疗法和nsMRA的作用。

主要发现

  • GLP-1RA在糖尿病肥胖合并CKD患者中具有肾脏保护作用,FLOW试验等临床研究支持其作用。
  • GLP-1RA在维持性透析的终末期肾病(ESKD)患者及肾移植后的作用证据较少但仍被讨论。
  • 其他肠激素疗法包括GLP-1/葡萄糖依赖性促胰岛素多肽双激动剂(替西帕肽)、三重激动剂(含胰高血糖素激动)和胰淀素类似物可能改善CKD患者的心血管和肾脏结局。
  • nsMRA等独立于肠-肾轴的新型疗法具有改善心肾结局的潜力。

关键数值与推荐

  • KDIGO CKD指南推荐已总结,但原文未列出具体推荐条款。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The interrelated pandemics of obesity and type 2 diabetes mellitus (T2DM) are fuelling an increase in the prevalence of chronic kidney disease (CKD), which amplifies the risk of cardiovascular events and may progress to end-stage kidney disease (ESKD). Treatment options for such patients have rapidly expanded over the past decade and continue to evolve. Herein, we primarily focus on glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their role in the management of CKD in the setting of overweight/obesity and T2DM. Recommendations from the recent Kidney Disease: Improving Global Outcomes CKD guidelines are summarized and new evidence arising since publication of these guidelines is highlighted. We review clinical studies supporting the role of GLP-1RAs in patients with diabesity and CKD, including the FLOW trial, as well as exploring potential mechanisms of their nephroprotective effects. Their role in the management of patients with ESKD on maintenance dialysis and after kidney transplantation, while less evidence-based, is also discussed. The potential for other gut hormone-based therapies, including GLP-1/glucose-dependent insulinotropic polypeptide dual agonists (tirzepatide), triple agonists (incorporating glucagon agonism) and amylin analogues to improve cardiovascular and kidney outcomes in patients with CKD, is explored. We highlight the role of novel therapies distinct from the gut-kidney axis, including non-steroidal mineralocorticoid receptor antagonists (nsMRAs). We outline the potential for multitarget therapy incorporating renin-angiotensin-aldosterone system inhibitors, sodium-glucose co-transporter-2 inhibitors, incretin-based treatments and nsMRAs to improve cardiovascular and kidney outcomes in patients with overweight/obesity and T2DM. Current unknowns in the timing and sequence of multitarget therapy in patients with CKD are emphasized. Priority research questions for the future are highlighted throughout the review.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Morales E, Martin WP, Bevc S, et al. How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA. Nephrol Dial Transplant. 2025. PMID: 40359159. doi:10.1093/ndt/gfaf069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。